Direct factor Xa inhibitors and the risk of cancer and cancer mortality: A Danish population-based cohort study.

ABSTRACT:

Background

Preclinical animal studies have suggested that myeloid cell-synthesized coagulation factor X dampens antitumor immunity and that rivaroxaban, a direct factor Xa inhibitor, can be used to promote tumor immunity. This study was aimed at assessing whether patients with atrial fibrillation taking direct factor Xa inhibitors have lower risk of cancer and cancer-related mortality than patients taking the direct thrombin inhibitor dabigatran.

Methods and findings

This nationwide population-based cohort study in Denmark included adult patients with atrial fibrillation and without a history of cancer, who started taking a factor Xa inhibitor or dabigatran between 2011 and 2015. Data on medical history, outcomes, and drug use were acquired through Danish healthcare registri

SUBMITTER: Bosch F 

PROVIDER: S-EPMC11251598 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature